Stockscreener 앱 받기
2.34
2.90%
-0.07
전일 마감가:
$2.41
열려 있는:
$2.37
하루 거래량:
5,430
Relative Volume:
0.37
시가총액:
$21.81M
수익:
-
순이익/손실:
$-20.74M
주가수익비율:
-0.9323
EPS:
-2.51
순현금흐름:
$-18.90M
1주 성능:
-7.51%
1개월 성능:
+17.59%
6개월 성능:
-18.75%
1년 성능:
-17.89%
1일 변동 폭
$2.36
$2.50
1주일 범위
$2.30
$2.55
52주 변동 폭
$1.87
$4.20
Lisata Therapeutics Inc Stock (LSTA) Company Profile
명칭
Lisata Therapeutics Inc
전화
908-229-2590
주소
110 ALLEN ROAD, BASKING RIDGE
LSTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
2.40 | 21.81M | 0 | -20.74M | -18.90M | -2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.20 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
657.38 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.98 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.07 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Lisata Therapeutics Inc 주식(LSTA)의 최신 뉴스
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025 - The Manila Times
Lisata Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Lisata Therapeutics Earnings: Solid Tumor Treatment Developer Reports Q1 2025 Results May 8 - Stock Titan
Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely? - Yahoo Finance
LSTALisata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Lisata Therapeutics (NASDAQ:LSTA) Shares Up 0.9% – Still a Buy? - Defense World
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI - Proactive financial news
Lisata Therapeutics announces research license with Catalent - MSN
Lisata Therapeutics CMO discusses potential for certepetide under Catalant license agreement - Proactive financial news
Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement - Proactive Investors
Market movers: Meta, HPE, Applied Digital, Lisata Therapeutics... - Proactive Investors
Lisata Therapeutics (LSTA) Partners with Catalent on Preclinical Study | LSTA Stock News - GuruFocus
Lisata Therapeutics Announces Research License with Catalent - GlobeNewswire
Lisata Therapeutics, Inc. Announces Research License with Catalent, Inc - marketscreener.com
Lisata falls after mid-stage data for anticancer agent - MSN
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’ - MarketScreener
Neostem stock plunges to 52-week low at $2.01 amid market challenges - Investing.com Australia
Neostem stock plunges to 52-week low at $2.01 amid market challenges By Investing.com - Investing.com South Africa
Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025 - Proactive financial news
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR.com
Lisata Therapeutics CEO discusses AI drug discovery collaborationICYMI - Proactive Investors
Lisata Therapeutics expands drug discovery with GATC AI collaboration - Proactive Investors USA
Lisata Therapeutics expands drug discovery with GATC AI collaboration | NASDAQ:LSTA - Proactive Investors
Lisata Therapeutics to Present at the Investival Showcase USA - The Manila Times
Can This Clinical-Stage Pharma Company Transform Solid Tumor Treatment? CEO Presents Next Month - StockTitan
Lisata Therapeutics and GATC Health Consummate First Step - GlobeNewswire
Market movers: General Motors, Moderna, CrowdStrike, Lisata... - Proactive Investors UK
Lisata Therapeutics And GATC Health Partner To Accelerate Drug Development Using AI Technology - Nasdaq
Lisata Therapeutics partners with GATC Health to advance AI-driven drug development - Proactive Investors UK
Can AI Revolutionize Lisata's Pancreatic Cancer Drug? New GATC Health Partnership Aims to Prove It - StockTitan
Neostem stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia
Neostem stock hits 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
Lisata Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid Financial Challenges - GuruFocus.com
Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ... - Yahoo
Lisata Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Earnings call transcript: Lisata Therapeutics Q4 2024 sees steady progress By Investing.com - Investing.com South Africa
Lisata Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Lisata Therapeutics Q4 2024 sees steady progress - Investing.com India
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2024 Earnings Call Transcript - Insider Monkey
Lisata Therapeutics CEO: 2025 to be ‘data-rich’ as certepetide trials progress - Proactive Investors UK
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Lisata Therapeutics Inc (LSTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):